The US Food and Drug Administration (FDA) is often criticized for delaying treatments for patients, especially those with terminal illnesses such as advanced cancer. However, a new drug-to-drug comparison (Roberts SH, et al. Health Aff [Millwood]. 2011;30:1375-1381) of the 35 new cancer drugs approved by the FDA and the European Medicines Agency (EMA) between 2003 and 2010 shows that: